We have corroborated our in vitro cytotoxic studies with in vivo xenograft models, where we observed a significant delay in tumor growth, using both the engineered HCT116 IDH1-mutant xenograft model, as well as the fibrosarcoma HT1080 xenograft model with an endogenous IDH1 R132C mutation. Here, IDH1 is linked to neoplasm.